| [1］Omer AK，Ziakas PD，Anagnostou T，Coughlin E，Kourkoumpetis T，McAfee SL，Dey BR，Attar E，Chen YB，Spitzer TR，Mylonakis E，Ballen KK.Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation：a single center experience.Biol Blood Marrow Transplant,2013，19(8)：1190-1196. [2］De Pauw B，Walsh TJ，Donnelly JP，et al.Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group(EORTC/MSG)Consensus Group.Clin Infect Dis，2008，46(12)：1813-1821. [3］中国侵袭性真菌感染工作组。血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第四次修订版)。中华内科杂志,2013，52(08)：704-709. [4］Kontoyiannis DP，Marr KA，Park BJ，et al.Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients，2001-2006：overview of the Transplant-Associated Infection Surveillance Network(TRANSNET)Database.Clin Infect Dis，2010，50(8)：1091-100. [5］Ullmann AJ，Akova M，Herbrecht R，et al.ESCMID* guideline for the diagnosis and management of Candida diseases 2012：adults with haematological malignancies and after haematopoietic stem cell transplantation(HCT).Clin Microbiol Infect，2012，18(Suppl 7)：53-67. [6］Herbrecht R，Denning DW，Patterson TF，et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N Engl J Med，2002，347(6)：408-415. [7］Lewis RE.Current concepts in antifungal pharmacology.Mayo Clin Proc，2011，86(8)：805-817. [8］Herbrecht R，Maertens J，Baila L，et al.Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients：an European Organisation for Research and Treatment of Cancer study.Bone Marrow Transplant，2010，45(7)：1227-1233. [9］Maertens J，Egerer G，Shin WS，et al.Caspofungin use in daily clinical practice for treatment of invasive aspergillosis：results of a prospective observational registry.BMC Infect Dis，2010，10：182. [10］Würthwein G，Young C，Lanvers-Kaminsky C，et al.Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.Antimicrob Agents Chemother，2012，56(1)：536-543. [11］De Castro N，Neuville S，Sarfati C，et al.Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation：a 6-year retrospective study.Bone Marrow Transplant，2005，36(10)：879-883. |
